Biocon

July 16 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - BIOCON MALAYSIA RECEIVES EMA APPROVAL FOR NEW DRUG PRODUCT FILL FINISH UNIT FOR INSULINS

Source text: ID:nnAZN4T822N

Further company coverage: BION.NS

(([email protected];))

Mylan Inc. disclosed on Tuesday that it sold its entire 5.64 percent stake in Biocon, selling 9.19 crore shares on the open market on July 14. The sale, worth approximately ₹4,000 crore at prevailing prices, completely exited the American pharmaceutical company from the Indian biopharmaceutical firm. Mylan and Biocon have shared a long-standing partnership in biosimilars, with Mylan previously holding the stake as a strategic investor. The disposal was disclosed under Regulation 29(2) of the SEBI Takeover Regulations. Mylan was not part of Biocon’s promoter group and had held the 5.64 percent stake without any encumbrances. Following the transaction, Mylan no longer holds any equity shares in the company. The exit may prompt investor questions about the future of the biosimilars alliance between the two firms.

Powered by Tijori

** Shares of Biocon BION.NS rise 5.3% to 432.85 rupees

** Nearly 46 mln shares of BION change hands via block deal on NSE at 400 rupees per share - exchange data showed

** Mylan Inc, part of healthcare company Viatris VTRS.O, planned to sell up to 92 mln shares in BION, worth up to 34.81 bln rupees ($362.1 mln), as per term sheet seen by Reuters

** YTD, BION up ~10%

($1 = 96.1350 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

SINGAPORE, July 13 (Reuters) - Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd BION.NS, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.

($1 = 95.6200 Indian rupees)

(Reporting by Yantoultra Ngui
Editing by Tomasz Janowski)

(([email protected];))

May 11 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - BIOCON PHARMA RECEIVES HEALTH CANADA APPROVAL FOR MICAFUNGIN FOR INJECTION, USP, 50 MG AND 100 MG

Source text: ID:nnAZN4SVCE2

Further company coverage: BION.NS

(([email protected];))

** Biocon BION.NS gains 2.68% to 392.50 rupees

** Drugmaker's Q4 consol net income rises ~2.6% y/y on growth led by biosimilars, generics businesses

** Revenue from generics up 13% y/y, biosimilars up 12%

** EBITDA rises 29% y/y

** Net profit before exceptional items rises 64% y/y; reported net profit drops ~63.5% y/y, hit by one-off exceptional charges

** Stock rated "buy" on average; median PT is 425 rupees, per data compiled by LSEG

** YTD, BION down ~1.36%, Nifty Pharma .NIPHARM up ~6%

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

May 5 (Reuters) -

• KIRAN MAZUMDAR-SHAW, FOUNDER AND CHAIRPERSON OF BIOCON IDENTIFIES NIECE CLAIRE MAZUMDAR AS SUCCESSOR- FORTUNE INDIA

Source text: [https://bit.ly/4tgQ6uv]

Further company coverage: BION.NS

(([email protected];))

May 4 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - BOARD TO CONSIDER INVESTMENT IN BIOCON BIOLOGICS VIA PREFERENTIAL EQUITY ALLOTMENT

Source text: ID:nBSE3FXwyN

Further company coverage: BION.NS

(([email protected];))

April 30 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - U.S. FDA COMPLETES PRE-LICENSE INSPECTION AT BIOCON'S BIOSIMILARS SITE IN BENGALURU

• BIOCON - U.S. FDA ISSUES FORM 483 WITH FIVE OBSERVATIONS AFTER INSPECTION

Source text: ID:nNSE5Z9qN5

Further company coverage: BION.NS

(([email protected];))

April 21 (Reuters) - Biocon Ltd BION.NS:

• RECEIVES HEALTH CANADA APPROVAL FOR BOSAYA AND VEVZUO BIOSIMILARS

Source text: ID:nBSE2TxjhJ

Further company coverage: BION.NS

(([email protected];))

April 8 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - UNIT RECEIVES U.S. FDA APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG

Source text: ID:nBSE8pdZnk

Further company coverage: BION.NS

(([email protected];;))

April 7 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - ANNOUNCES U.S. COMMERCIAL LAUNCH OF BOSAYA AND AUKELSO, DENOSUMAB BIOSIMILARS

Source text: ID:nBSE10Z4f4

Further company coverage: BION.NS

(([email protected];;))

March 27 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - SIDDHARTH MITTAL TO STEP DOWN AS CEO AND MANAGING DIRECTOR EFFECTIVE MARCH 31, 2026

• BIOCON - APPOINTS SHREEHAS PRADEEP TAMBE AS CEO AND MANAGING DIRECTOR EFFECTIVE APRIL 1, 2026

• BIOCON - MUKESH KAMATH TO STEP DOWN AS INTERIM CHIEF FINANCIAL OFFICER

• BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER EFFECTIVE APRIL 1, 2026

• BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER

Source text: ID:nBSE5rJf10

Further company coverage: BION.NS

(([email protected];))

Feb 24 (Reuters) - Biocon Ltd BION.NS:

• BIOCON OBTAINS APPROVAL FOR WEIGHT MANAGEMENT DRUG LIRAGLUTIDE IN THE UNITED STATES

Source text: [ID:]

Further company coverage: BION.NS

(([email protected];;))

Repeats story from 13th Feburary with no changes to text

By Rishika Sadam

Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.

Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.

It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.

The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.

"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.

In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.

The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.

Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.

India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.

(Reporting by Rishika Sadam; Editing by Tasim Zahid)

(([email protected];))

By Rishika Sadam

Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.

Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.

It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.

The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.

"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.

In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.

The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.

Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.

India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.

(Reporting by Rishika Sadam; Editing by Tasim Zahid)

(([email protected];))

Feb 12 (Reuters) - Biocon Ltd BION.NS:

• Q3 CONSOL NET PROFIT 1.44 BILLION RUPEES

• Q3 CONSOL TOTAL INCOME 42.9 BILLION RUPEES

• ONE-TIME CHARGE OF 2.93 BILLION RUPEES IN Q3

Source text: [ID:]

Further company coverage: BION.NS

(([email protected];;))

Feb 7 - Biocon Biologics Ltd BIOC.NS:

• BIOCON - FITCH RATINGS UPS UNIT BIOCON BIOLOGICS OUTLOOK TO POSITIVE FROM STABLE

Source text: [ID:]

Further company coverage: BIOC.NS

Jan 28 (Reuters) - Biocon Ltd BION.NS:

• RECEIVES VAI STATUS FROM US FDA FOR ANDHRA PRADESH FACILITY

• US FDA INSPECTION CONDUCTED BETWEEN NOVEMBER 3 AND 7, 2025

Source text: ID:nNSEbKKsRs

Further company coverage: BION.NS

(([email protected];))

Jan 21 (Reuters) - Biocon Ltd BION.NS:

• NOW HOLDS 98% OF BIOCON BIOLOGICS' EQUITY SHARE CAPITAL

Source text: ID:nBSE4qZGqt

Further company coverage: BION.NS

(([email protected];;))

Jan 12 (Reuters) - Biocon Ltd BION.NS:

• BIOCON - UNIT GETS APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EVEROLIMUS TABLETS

Source text: ID:nBSE5fN5Mc

Further company coverage: BION.NS

(([email protected];;))

Jan 6 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS TO EXPAND BIOSIMILAR ONCOLOGY PORTFOLIO

Further company coverage: BION.NS

(([email protected];))

Jan 2 (Reuters) - Biocon Ltd BION.NS:

• ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES

Source text: ID:nBSEbBWRB3

Further company coverage: BION.NS

(([email protected];))

** Biocon's BION.NS acquisition of minority stake in biosimilars unit Biocon Biologics BIOC.NS to make it wholly-owned subsidiary will remove holding company discount, add ~10% to Biocon's valuation, says JM Financial

** Retains "buy", with PT of 476 rupees; on avg, stock rated "buy", median PT is 435 rupees

** ICICI Securities says deal values Biocon Biologics at $5.5 bln, higher than earlier contemplated $4.5 billion

** Adds stake buy will lead to significant dilution - from 54% to 44% for promoters, from 46% to 37% for non-promoters

** Notes positive impact of holding co discount removal to nullify dilution concerns

** BION rises 7.47% this year, as of last close

(Reporting by Abhirami G in Bengaluru)

(([email protected]))

** Shares of Biocon BION.NS fall 5.3% to 388 rupees, hitting their lowest in three weeks

** Pharma co to consider investment in Biocon Biologics via purchase of shares from existing shareholders for cash or through issuance of shares of co

** Systematix Institutional Equities analyst Vishal Manchanda says that to buyout minority interest in Biocon Biologics, BION may have to raise 100-150 billion rupees ($1.1 - $1.7 billion), which would mean meaningful dilution for shareholders of the company

** BION set for worst day since August 8

** Avg rating of 16 analysts covering the stock is "buy", their median PT is 433 rupees - data complied by LSEG

** Session's losses trim YTD gains to 6%

(Reporting by Nishit Navin in Bengaluru)

(([email protected]))

By Rishika Sadam

Nov 13 (Reuters) - India's Biocon BION.NS expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.

Biosimilars are copies of costlier biological drugs used to treat major illnesses such as cancer, rheumatoid arthritis, psoriasis and diabetes. The U.S. Food and Drug Administration last month proposed to simplify drug testing by lowering the requirement for large comparative clinical efficacy trials.

Biocon, which aims to cumulatively launch 20 biosimilars by 2030, is focusing on upcoming launches in the key markets of U.S. and Europe, Shreehas Tambe, CEO of Biocon Biologics, a unit of Biocon, said in an interview.

"You can do more because it's (FDA's draft proposal) going to halve the cost of development ... you can develop them (biosimilars) and bring them to patients faster and make it more affordable."

Biocon, which has seven of its biosimilars in the commercial market in the U.S., is looking to launch two more in the next six months. The company's oncology biosimilar medicines have a fourth of the U.S. market share and will benefit from the lower development cost, Tambe said.

The firm's revenue from biosimilars grew 25% in the latest quarter.

Biocon is also looking to expand its generics segment with the launch of weight-loss drugs to drive future growth, the company had said earlier.

(Reporting by Rishika Sadam; Editing by Harikrishnan Nair)

(([email protected];))

Oct 16 (Reuters) - Biocon Ltd BION.NS:

• BIOCON BIOLOGICS AND CIVICA EXPAND PARTNERSHIP AND LAUNCH PRIVATE-LABEL INSULIN GLARGINE TO BROADEN U.S. DIABETES TREATMENT OPTIONS

Source text: ID:nPn8Sc4Msa

Further company coverage: BION.NS

(([email protected];))

** Biocon BION.NS falls 1.5% to 348 rupees; set to snap four-session gaining streak

** Biopharmaceutical co's U.S. manufacturing site in New Jersey's Cranbury gets one observation from U.S. FDA post inspection

** Cranbury site inaugurated last month

** Co says it will address observation within stipulated time; observation not expected to have any impact on business operations

** BION down ~5% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Rewrites, updates shares, adds analysts' comments

By Ananta Agarwal and Rishika Sadam

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2% on Friday after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented drugs, effective Oct. 1.

The U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs.

Of the 20 index constituents, 18 traded in the red as of 2:37 p.m. IST.

Analysts described the decline as "sentimental", noting that India's exports to the U.S. are primarily generic medicines, which may not be affected by the tariffs.

Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue and the heaviest stock on the index, fell about 3%. Sun Pharma markets patented drugs, including Ilumya, a psoriasis treatment approved by the U.S. FDA.

The company also has a contract manufacturing unit through EU partners for specialty drugs, where a 15% tariff applies to EU exports to the U.S., according to Vishal Manchanda, equity analyst at Systematix Group.

"The impact on Sun is not very meaningful," he said. "It may be between 1% to 3% of EBITDA."

Laurus Labs LAUL.NS declined the most among constituents of the index, down about 6%.

"There is a general worry that CDMO (contract drug manufacturing organisations) might be impacted as the U.S. moves manufacturing in-house," Manchanda added.

Biocon, which makes complex biosimilars for cancer treatment and has significant U.S. exposure, is down about 4.6%.

"Uncertainty remains whether complex generics and biosimilars will face future tariffs," ICICI Securities analyst Pankaj Pandey said in a note on Friday.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee and Janane Venkatraman)

(([email protected];))